Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1Phase 1/2 1Phase 1 1

Status

Completed 3Withdrawn 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Pancreatic Neoplasms 3Pancreatic Cancer Non-resectable 1Neoplasms 1

Interventions

Oxaliplatin 1439Fluorouracil 1319Capecitabine 1114Gemcitabine 1057Leucovorin 939Bevacizumab 847Irinotecan 830Cisplatin 676Radiotherapy 560Cetuximab 482pembrolizumab 435Paclitaxel 401Drug Therapy 358Nivolumab 350130-nm albumin-bound paclitaxel 329Docetaxel 290Sorafenib 288S 1 (combination) 279Folfox protocol 266Albumin-Bound Paclitaxel 263Surgical Procedures, Operative 258lenvatinib 222sintilimab 218tislelizumab 214durvalumab 212regorafenib 209Magnetic Resonance Spectroscopy 205apatinib 204Radiosurgery 204Neoadjuvant Therapy 190

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
pamrevlumab × Gastrointestinal × Clear all
NCT03941093 2024-11-05

LAPIS

Kyntra Bio

Phase 3 Completed
284 enrolled 14 charts
Gastrointestinal

Pancreatic Cancer Non-resectable

NCT02210559 2023-03-02

A Study of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 in Participants With Locally Advanced, Unresectable Pancreatic Cancer

Kyntra Bio

Phase 1/2 Completed
37 enrolled 16 charts
Gastrointestinal

Neoplasms, Pancreatic Neoplasms

NCT02851381 2016-10-07

Compassionate Single Subject Use of FG-3019 (FibroGen) in Locally Advanced, Unresectable Pancreatic Cancer

Jonsson Comprehensive Cancer Center

Phase NA Withdrawn
Gastrointestinal

Pancreatic Neoplasms

NCT01181245 2014-08-06

A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer

Kyntra Bio

Phase 1 Completed
50 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡